Status:
COMPLETED
Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer
Lead Sponsor:
Ganymed Pharmaceuticals GmbH
Conditions:
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
IMAB362 is a monoclonal antibody specific for gastric or lower esophageal adenocarcinoma. Preclinically IMAB362 was shown to inhibit tumor growth and to kill cancer cells by indirect (complement-depen...
Eligibility Criteria
Inclusion
- Metastatic, refractory or recurrent disease of advanced adenocarcinoma of the stomach or the lower esophagus proven by histology
- CLDN18.2 expression of the biopsy material from the cancer confirmed by immunohistochemistry
- At least 1 measurable site of disease according to RECIST criteria
Exclusion
- Less than 3 weeks since prior chemo-or radiation therapy
- Other concurrent anticancer therapies
- Concurrent anticoagulation with vitamin K antagonists
- Therapeutic doses of Heparin (prophylactic doses accepted)
- Uncontrolled or severe illness
Key Trial Info
Start Date :
September 3 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 13 2015
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT01197885
Start Date
September 3 2010
End Date
August 13 2015
Last Update
June 13 2025
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Dispensary "Dr. Marko Markov"
Varna, Bulgaria, 9002
2
MHAT "St.Marina"
Varna, Bulgaria, 9010
3
Complex Oncology Center
Veliko Tarnovo, Bulgaria, 5000
4
Charité - Universitätsmedizin Berlin
Berlin, Germany, 13353